For the first time in history, we now have an FDA-approved treatment for Parkinson’s disease Psychosis.  It’s great news for longs and patients that have been suffering from grueling hallucinations associated with PDP.

While the FDA has asked for a black box warning due to increased risk of death associated with use in older people, the news is great for ACADIA Pharmaceuticals (ACAD).  Nearly 40% of all Parkinson’s patients develop PDP along the way.

Now with treatment, they may not have to suffer much longer. 

With approval in hand, the drug – Nuplazid – is expected to price near $13,500 per patient a year and reach a billion dollars in sales within four years. 

Parkinson’s disease PsychosisWhat’s fascinating is this.  Since recommending ACADIA at $1.05 and $1.24 in 2010, we’ve watched the stock soar to $51.99 for gains of 4,851% and 4,093%.  It’s since pulled back but the gains are tough to ignore… with more upside likely for what some are calling a billion-dollar drug.

Congratulations to all longs that followed our advice.  Job well done…

Leave a Reply

Your email address will not be published. Required fields are marked *

Post comment